Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
29
09
2020
accepted:
17
12
2020
pubmed:
25
1
2021
medline:
9
7
2021
entrez:
24
1
2021
Statut:
ppublish
Résumé
A significant proportion of deaths from cutaneous melanoma occur among patients with an initial diagnosis of stage 1 or 2 disease. The Decision-Dx Melanoma (DDM) 31-gene assay attempts to stratify these patients by risk of recurrence. This study aimed to evaluate this assay in a large single-institution series. A retrospective chart review of all patients who underwent surgery for melanoma at a large academic cancer center with DDM results was performed. Patient demographics, tumor pathologic characteristics, sentinel node status, gene expression profile (GEP) class, and recurrence-free survival (RFS) were reviewed. The primary outcomes were recurrence of melanoma and distant metastatic recurrence. Data from 361 patients were analyzed. The median follow-up period was 15 months. Sentinel node biopsy was performed for 75.9% (n = 274) of the patients, 53 (19.4%) of whom tested positive. Overall, 13.6% (n = 49) of the patients had recurrence, and 8% (n = 29) had distant metastatic recurrence. The 3- and 5-year RFS rates were respectively 85% and 75% for the class 1A group, 74% and 47% for the class 1B/class 2A group, and 54% and 45% for the class 2B group. Increased Breslow thickness, ulceration, mitoses, sentinel node biopsy positivity, and GEP class 2B status were significantly associated with RFS and distant metastasis-free survival (DMFS) in the univariate analysis (all p < 0.05). In the multivariate analysis, only Breslow thickness and ulceration were associated with RFS (p < 0.003), and only Breslow thickness was associated with DMFS (p < 0.001). Genetic profiling of cutaneous melanoma can assist in predicting recurrence and help determine the need for close surveillance. However, traditional pathologic factors remain the strongest independent predictors of recurrence risk.
Sections du résumé
BACKGROUND
BACKGROUND
A significant proportion of deaths from cutaneous melanoma occur among patients with an initial diagnosis of stage 1 or 2 disease. The Decision-Dx Melanoma (DDM) 31-gene assay attempts to stratify these patients by risk of recurrence. This study aimed to evaluate this assay in a large single-institution series.
METHODS
METHODS
A retrospective chart review of all patients who underwent surgery for melanoma at a large academic cancer center with DDM results was performed. Patient demographics, tumor pathologic characteristics, sentinel node status, gene expression profile (GEP) class, and recurrence-free survival (RFS) were reviewed. The primary outcomes were recurrence of melanoma and distant metastatic recurrence.
RESULTS
RESULTS
Data from 361 patients were analyzed. The median follow-up period was 15 months. Sentinel node biopsy was performed for 75.9% (n = 274) of the patients, 53 (19.4%) of whom tested positive. Overall, 13.6% (n = 49) of the patients had recurrence, and 8% (n = 29) had distant metastatic recurrence. The 3- and 5-year RFS rates were respectively 85% and 75% for the class 1A group, 74% and 47% for the class 1B/class 2A group, and 54% and 45% for the class 2B group. Increased Breslow thickness, ulceration, mitoses, sentinel node biopsy positivity, and GEP class 2B status were significantly associated with RFS and distant metastasis-free survival (DMFS) in the univariate analysis (all p < 0.05). In the multivariate analysis, only Breslow thickness and ulceration were associated with RFS (p < 0.003), and only Breslow thickness was associated with DMFS (p < 0.001).
CONCLUSION
CONCLUSIONS
Genetic profiling of cutaneous melanoma can assist in predicting recurrence and help determine the need for close surveillance. However, traditional pathologic factors remain the strongest independent predictors of recurrence risk.
Identifiants
pubmed: 33486642
doi: 10.1245/s10434-020-09563-7
pii: 10.1245/s10434-020-09563-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4582-4589Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551 .
doi: 10.3322/caac.21551
pubmed: 30620402
Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32:1599–604. https://doi.org/10.1080/03007995.2016.1192997 .
doi: 10.1080/03007995.2016.1192997
pubmed: 27210115
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206. https://doi.org/10.1200/jco.2009.23.4799 .
doi: 10.1200/JCO.2009.23.4799
pubmed: 19917835
pmcid: 2793035
Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (≤ 1 mm) than from thick melanomas (> 4 mm) in Queensland, Australia. J Invest Dermatol. 2015;135:1190–3. https://doi.org/10.1038/jid.2014.452 .
doi: 10.1038/jid.2014.452
pubmed: 25330295
Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989–2009. J Natl Cancer Inst. 2016;108:1–7. https://doi.org/10.1093/jnci/djv294 .
doi: 10.1093/jnci/djv294
Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019. JNCCN J Natl Compr Cancer Netw. 2019;17:367–402. https://doi.org/10.6004/jnccn.2019.0018 .
Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group Report Number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596–603. https://doi.org/10.1016/j.ophtha.2012.02.017 .
doi: 10.1016/j.ophtha.2012.02.017
pubmed: 22521086
Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175–83. https://doi.org/10.1158/1078-0432.ccr-13-3316 .
doi: 10.1158/1078-0432.CCR-13-3316
pubmed: 25564571
Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18:1–11. https://doi.org/10.1186/s12885-018-4016-3 .
doi: 10.1186/s12885-018-4016-3
Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019;8:2205–12. https://doi.org/10.1002/cam4.2128 .
doi: 10.1002/cam4.2128
pubmed: 30950242
pmcid: 6536922
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92. https://doi.org/10.3322/caac.21409 .
Greenhaw BN, Covington KR, Kurley SJ, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1479 patients. J Am Acad Dermatol. Published online 2020. https://doi.org/10.1016/j.jaad.2020.03.053.%3caq6 >
doi: 10.1016/j.jaad.2020.03.053.<AQ6>
Kovarik CL, Chu EY, Adamson AS. Gene expression profile-testing for thin melanoma. JAMA Dermatology. 2020;156:837. https://doi.org/10.1001/jamadermatol.2020.0894 .
doi: 10.1001/jamadermatol.2020.0894
pubmed: 32293654
Hu Y, Briggs A, Marchetti MA, Ariyan CE, Coit DG, Bartlett EK. Cost-benefit implication of gene expression profiling and adjuvant therapy in stage IIIA melanoma. J Am Coll Surg. 2020;231:547–54.e1. https://doi.org/10.1016/j.jamcollsurg.2020.08.750 .
doi: 10.1016/j.jamcollsurg.2020.08.750
Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780–5.e3. https://doi.org/10.1016/j.jaad.2015.01.009 .
doi: 10.1016/j.jaad.2015.01.009
Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80:149–57.e4. https://doi.org/10.1016/j.jaad.2018.07.028 .
doi: 10.1016/j.jaad.2018.07.028
Luke JJ, Ascierto PA, Carlino MS, et al. KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Futur Oncol. 2019;16:4429–38. https://doi.org/10.2217/fon-2019-0666 .
doi: 10.2217/fon-2019-0666
Klapperich ME, Bowen GM, Grossman D. Current controversies in early-stage melanoma: questions on management and surveillance. J Am Acad Dermatol. 2019;80:15–25. https://doi.org/10.1016/j.jaad.2018.03.054 .
doi: 10.1016/j.jaad.2018.03.054
pubmed: 30553299
Grossman D, Kim CC, Hartman RI, et al. Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Manag. 2019;6:MMT32. https://doi.org/10.2217/mmt-2019-0016 .
Marchetti MA, Bartlett EK, Dusza SW, Bichakjian CK. Use of a prognostic gene expression profile test for T1 cutaneous melanoma: will it help or harm patients? J Am Acad Dermatol. 2019;80:e161–2. https://doi.org/10.1016/j.jaad.2018.11.063 .
doi: 10.1016/j.jaad.2018.11.063
pubmed: 30586612
Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75:516–24. https://doi.org/10.1016/j.jaad.2016.02.1229 .
doi: 10.1016/j.jaad.2016.02.1229
pubmed: 27183845
Varedi A, Gardner LJ, Kim CC, et al. Use of new molecular tests for melanoma by pigmented-lesion experts. J Am Acad Dermatol. 2020;82:245–7. https://doi.org/10.1016/j.jaad.2019.08.022 .
doi: 10.1016/j.jaad.2019.08.022
pubmed: 31415835
Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208–50. https://doi.org/10.1016/j.jaad.2018.08.055 .
doi: 10.1016/j.jaad.2018.08.055
pubmed: 30392755